In a world with COVID-19 travel restrictions, MILabs has remotely completed the installation of a new E-Class VECTor6 system at the Osaka University of Pharmaceutical Sciences, Osaka, Japan. With the help of a local technician, this top-of-the-line multimodality PET/SPECT/CT system was put into operation by remote control from MILabs’ support facility in the Netherlands.
According to Prof. Takashi Temma, Ph.D., Director of the Department of Biofunctional Analysis: “We are impressed by the robust design and remote support capabilities of this complex multimodal PET-SPECT-CT system. Besides delivering excellent imaging performance for each modality, the system also has the unique ability to run two assays labeled with different PET isotopes or PET/SPECT isotopes concurrently, in the same animal. Since we develop new diagnostic probes for biofunctional analysis, this MILabs system gives us the power advantage of within-subjects designs, resulting in more reliable results and the use of fewer disease models.”
Prof. Frederik Beekman, Ph.D., CEO/CSO comments: “We are excited that despite travel bans, we could get Prof. Temma’s system up and running for his routine use through remote control from our offices. The unique concurrent imaging capabilities of this multimodal system enables in a single imaging session to deliver more statistically reliable results than any other multimodal in-vivo imaging setup.”
Ad Statistics
Times Displayed: 21862
Times Visited: 433 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
About Osaka University of Pharmaceutical Sciences :
The Osaka University of Pharmaceutical Sciences is dedicated to education and research in pharmaceutical sciences. Among its research objectives are the development of diagnostic and therapeutic methods using animal disease model by employing molecular imaging for early functional diagnosis, and evaluation of therapeutic effects on cancers. More specifically, the Biofunctional Analysis laboratory is focused on the design and development of radiolabeled probes for PET and SPECT imaging.
About MILabs B.V.
MILabs is a fast-growing Dutch company that has been providing a continuum of innovations to expand the applications of preclinical imaging. Today, MILabs has succeeded at commercializing a scalable imaging platform, able to accommodate nuclear, optical, and X-ray CT imaging techniques. The company provides multimodal imaging systems with the highest resolution available in the industry. Its products are used by biotech and pharmaceutical companies as well as academic research institutions worldwide to accelerate the development of new vaccines, therapies, and diagnostics.
Back to HCB News
